Trial Profile
A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (NV-AMD)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Mecamylamine (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors CoMentis
- 19 May 2014 New trial record